ABSTRACT
Rationale Genome wide association studies (GWAS) have associated >100 genetic loci with atrial fibrillation (AF), yet the biological pathways of AF remain elusive.
Objective To determine candidate causal genes associated with AF risk loci and their coexpression partners, modules, biologic and mechanistic pathways.
Methods and Results Cis-expression quantitative trait loci (eQTLs) were identified for candidate genes near AF risk single nucleotide polymorphisms (SNPs) in human left atrial tissues. Genes were categorized into 3 sets according to likelihood of being a causative AF gene: 1) All Candidate Genes (with significant eQTLs or previously prioritized); 2) Any eQTL Genes (with ≥1 significant eQTL); and 3) Top GWAS SNP eQTL Genes (top SNP within the top 10 eQTL SNPs). Coexpression partners were identified for each candidate gene. Weighted gene coexpression network analysis (WGCNA) identified modules and modules with overrepresentation of candidate AF genes. Ingenuity Pathway Analysis (IPA) was applied to the coexpression partners of each candidate gene, and IPA and gene set enrichment analysis (GSEA) to each WGCNA module. 166 AF-risk SNPs were located in 135 distinct loci. The All Candidate Genes group contained 233, the Any eQTL Genes group 131 (83 novel), and the Top GWAS SNP eQTL Genes group 37 genes. IPA identified mitochondrial dysfunction, oxidative stress, epithelial adherens junction signaling, and sirtuin signaling as the most frequent pathways. WGCNA characterized 64 modules; candidate AF genes were overrepresented in 8. Modules were represented by cell injury, death, stress, developmental, metabolic/mitochondrial, transcription/translation, and immune activation/inflammation regulatory pathways.
Conclusions AF candidate gene coexpression analyses suggest significant roles for cellular stress and remodeling in AF. We propose a dual risk model for AF: Genetic susceptibility to AF may not manifest until later in life, when cellular stressors overwhelm adaptive responses. These analyses provide a resource for further functional studies on potential causal AF genes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Institutes of Health grants R01 HL 090620 and R01 HL 111314; American Heart Association Atrial Fibrillation Strategically Focused Research Network grant 18SFRN34110067, 18SFRN34170013, 18SFRN34140065, 18SFRN34170442; the NIH National Center for Research Resources for Case Western Reserve University and Cleveland Clinic Clinical and Translational Science Award UL1-RR024989, the Cleveland Clinic Department of Cardiovascular Medicine philanthropy research funds, and the Tomsich Atrial Fibrillation Research Fund. JH was supported by the National Institutes of Health training grant T32 GM 088088. JDS was supported by the Geoffrey Gund Endowed Chair for Cardiovascular Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Cleveland Clinic IRB #09-176
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Gene read counts are available in the Gene Expression Omnibus database (GSE69890)
